Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
February 02, 2023 08:02 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
January 27, 2023 16:03 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
January 25, 2023 08:01 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering
January 24, 2023 21:19 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Announces Proposed Public Offering of Common Stock
January 23, 2023 16:01 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis
January 22, 2023 14:00 ET
|
Pliant Therapeutics, Inc.
Bexotegrast demonstrated statistically significant increase in FVC at 4, 8 and 12 weeks of treatment, outperforming lower dose groups No bexotegrast-treated patients experienced disease...
Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 08:00 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis
December 15, 2022 08:00 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics (NASDAQ: PLRX) announced today that its lead drug candidate, bexotegrast (PLN-74809), an oral, once daily,...
Pliant Therapeutics to Participate in Upcoming Investor Conferences
November 15, 2022 08:00 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 08, 2022 16:02 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...